Original: Bevacizumab is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer.
Simplified: Bevacizumab is an anti-angiogenic drug that is used in the treatment of Metastatic Renal cell carcinoma, Metastatic breast cancer, Non-small cell lung cancer, and is also approved in the treatment Glioblastoma multiforme.